Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF)
(FSE: 31R) (“Revive” or the “Company”), a specialty
cannabis company focused on the research, development and
commercialization of novel cannabinoid-based products, is pleased
to provide a corporate update on its product strategy and business
development activities in its objective in offering best-in-class
products with first mover advantage in the multi-billion global
cannabis market.
“Over the last 18 months Revive has been focused
on establishing strategic relationships and building its product
and intellectual property portfolio to support our ambitions in
becoming a leading global specialty cannabis company,” said Fabio
Chianelli, President of Revive. “We look forward to our next
phase of our growth in launching novel and unique cannabis-based
products and partnering with leading licensed producers of cannabis
and pharmaceutical companies worldwide.”
Product Strategy
Revive is focused on commercializing
differentiated cannabis-based products that have patent
protection and best-in-class with first mover advantage offering a
better alternative over conventional cannabis-based products in the
market. The Company’s patent portfolio includes exclusive
rights to five issued U.S. patents, one issued Canadian patent and
two patent applications filed in the U.S., based on cannabinoid
delivery systems and uses for specific diseases. The
Company’s first product to be launched in Canada is a proprietary,
unique hemp-based cannabidiol (“CBD”) chewing gum, which Revive
signed an exclusive distribution and license agreement with AXIM®
Biotechnologies, Inc. to market the product throughout
Canada. The Company anticipates launching its hemp-based CBD
chewing gum product under Revive’s brand in the fourth quarter of
this year.
The Company’s strategy is to launch its
cannabis-based products in Canada as recognized under the proposed
regulations of Cannabis and Health Canada’s Natural Health Products
and Food and Drug regulations, with the objective to sell through
legalized distribution channels, national retailers in the food,
drug, mass market, and specialty and natural retail channels, be
included in health insurance plans, and distributed to countries
globally.
The Company’s advantageous position in Canada
will allow it to gather invaluable patient data and real-world
consumer experience of its products that will pave the way for new
products, improved product labelling and marketing, expansion in
major markets globally, and support potential new drug applications
for future pharmaceutical cannabinoid-based products.
Revive’s product portfolio will be a robust
assortment of premium unique dosage offerings, such as, but not
limited to, chewing gums, topicals, and alternate oral forms
putting an emphasis on the wellness market. The potential
advantages of Revive’s products over conventional dosage forms of
cannabis aim to achieve the following:
- Better bioavailability, while
bypassing the first-pass hepatic metabolism;
- Faster and reliable onset of
action;
- Precise dosing that is consistent,
accurate and repeatable;
- Avoid irritation in the lungs,
throat and stomach;
- Ease of use for improved consumer
and patient adherence and compliance;
- Higher acceptance for those who
find smoking or swallowing difficult; and
- Potential for improved blood
circulation to brain, cognitive function, and oral hygiene.
Business Development
Revive is in discussions with leading Canadian
licensed producers of cannabis to evaluate strategic collaborations
for the Company’s products, cannabinoid delivery system, liver
research program, and intellectual property in developing and
commercializing products for the cannabis and wellness market.
The Company has secured and is also evaluating exclusive
rights to unique cannabis-based products and technologies for the
Canadian market. Lastly, the Company is in discussion with a
potential biopharmaceutical company for its non-core pharmaceutical
program, bucillamine for the potential treatment in cystinuria and
gout.
About Revive Therapeutics
Ltd.
Revive Therapeutics Ltd. (TSX VENTURE: RVV)
(OTCQB: RVVTF) (FSE: 31R) is a specialty cannabis company focused
on the research, development and commercialization of novel
cannabinoid-based products. Revive is commercializing
patent-protected, best-in-class cannabis-based products with first
mover advantage in the multi-billion cannabis and wellness market.
The Company’s first commercial product is a proprietary
hemp-based cannabidiol (“CBD”) chewing gum for the wellness market
offering a better alternative over conventional products. The
Company’s novel cannabinoid delivery technology is being advanced
to fill the unmet medical needs for diseases and disorders such as
pain, inflammation, and wound care. Revive’s cannabinoid
pharmaceutical portfolio focus’ on rare liver diseases, which the
FDA granted to the Company orphan drug designation for CBD in the
treatment of autoimmune hepatitis.
For more information visit:
www.ReviveThera.com.
Neither the TSX-V nor its Regulation Services
Provider (as that term is defined in the policies of the TSX-V)
accepts responsibility for the adequacy or accuracy of this
release.
Revive Therapeutics Ltd. Cautionary Note
Regarding Forward-Looking Statements
This news release includes certain information
and statements about management's view of future events,
expectations, plans and prospects that constitute "forward-looking
information" that involves known and unknown risks and
uncertainties, which are not comprised of historical facts, and
most of which are beyond the control of Revive. Forward-looking
statements include estimates and statements that describe Revive’s
future plans, objectives or goals, including words to the effect
that Revive or its management expects a stated condition or result
to occur. Forward-looking statements may be identified by such
terms as "believes", "anticipates", "intends", "expects",
"estimates", "may", "could", "would", "will", “potential”, or
"plan", and similar expressions. Specifically, forward-looking
statements in this news release include, without limitation,
statements regarding: Revive’s exclusive distribution and license
agreement with AXIM® Biotechnologies, Inc.; Revive’s drug research
and development, and commercialization plans; Revive’s branded
cannabis-based products; Revive’s Bucillamine program; the timing
of operations; and estimates of market conditions. These statements
involve known and unknown risks, uncertainties, and other factors
that may cause actual results or events, performance, or
achievements of Revive to differ materially from those anticipated
or implied in such forward-looking statements. Since
forward-looking statements are based on assumptions and address
future events and conditions, by their very nature they involve
inherent risks and uncertainties. Revive believes that the
expectations reflected in these forward-looking statements are
reasonable, but there can be no assurance that actual results will
meet management's expectations. In formulating the forward-looking
statements contained herein, management has assumed: that business
and economic conditions affecting Revive will continue
substantially in the ordinary course and will be favourable to
Revive; that clinical testing results will justify
commercialization of the Revive’s product candidates; that Revive
will be able to obtain all requisite regulatory approvals to
commercialize its product candidates; that such approvals will be
received on a timely basis; and, that Revive will be able to find
suitable partners for development and commercialization of its
product candidates on favourable terms. Although these assumptions
were considered reasonable by management at the time of
preparation, they may prove to be incorrect and no assurance can be
given that such events will occur in the disclosed time frames or
at all.
Factors that may cause actual results to differ
materially from those anticipated by these forward-looking
statements include: uncertainties associated with obtaining
regulatory approval to perform clinical trials and market products;
the need to establish additional corporate collaborations,
distribution or licensing arrangements; Revive’s ability to raise
additional capital if and when necessary; intellectual property
disputes; increased competition from pharmaceutical and
biotechnology companies; changes in equity markets, inflation, and
changes in exchange rates; and other factors as described in detail
in Revive's Management's Discussion & Analysis for the period
ended June 30, 2017 and Revive's other public filings, all of which
may be viewed on SEDAR (www.sedar.com). Given these risks and
uncertainties, readers are cautioned not to place undue reliance on
such forward-looking statements and information, which are
qualified in their entirety by this cautionary statement. Except as
required by law, Revive disclaims any intention and assumes no
obligation to update or revise any forward-looking statements to
reflect actual results, whether as a result of new information,
future events, changes in assumptions, changes in factors affecting
such forward-looking statements or otherwise.
For more information please contact:
Craig LeonChief Executive OfficerRevive
Therapeutics Ltd.Tel: (416) 272-5525Email:
craig@revivethera.comWebsite: www.Revivethera.com
Revive Therapeutics (TSXV:RVV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Revive Therapeutics (TSXV:RVV)
Historical Stock Chart
From Jul 2023 to Jul 2024